Ezetimibe
- Generic Name
- Ezetimibe
- Brand Names
- Ezetrol, Lypqozet, Nexlizet, Roszet, Vytorin, Zetia
- Drug Type
- Small Molecule
- Chemical Formula
- C24H21F2NO3
- CAS Number
- 163222-33-1
- Unique Ingredient Identifier
- EOR26LQQ24
- Background
Ezetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in rats revealed that it was being localized within enterocytes of the intestinal villi - this prompted studies investigating ...
- Indication
Ezetimibe is indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with primary hyperlipidemia, alone or in combination with an HMG-CoA reductase inhibitor (statin). It is also indicated to reduce elevated total-C, LDL-C, Apo B, and non-HDL-C in patients with mixed hyperlipidemia in combination with fenofibrate, and to reduce elevated...
- Associated Conditions
- Elevated Blood Lipids, Elevated sitosterol and campesterol
- Associated Therapies
- -
Effectiveness and Safety of Ezetimibe Added to Atorvastatin in Patients With High Cholesterol and Coronary Heart Disease (Study P03740)
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2022-02-16
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 81
- Registration Number
- NCT00202904
A 16 Week Comparative Study of Fenofibrate Versus Ezetimibe as Add-on Therapy to Atorvastatin
- Conditions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2007-10-04
- Lead Sponsor
- Abbott
- Target Recruit Count
- 174
- Registration Number
- NCT00195793
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction
- Conditions
- Interventions
- First Posted Date
- 2005-09-20
- Last Posted Date
- 2014-08-12
- Target Recruit Count
- 30
- Registration Number
- NCT00203476
- Locations
- 🇺🇸
Tuscaloosa Research & Education Advancement Corporation, Tuscaloosa, Alabama, United States
Effect of Combination Therapy With Two Drugs (Colesevelam and Ezetimibe) in Patients With High Cholesterol
- Conditions
- First Posted Date
- 2005-09-16
- Last Posted Date
- 2007-09-11
- Lead Sponsor
- Daiichi Sankyo
- Target Recruit Count
- 45
- Registration Number
- NCT00185107
- Locations
- 🇺🇸
Medical Office, Statesville, North Carolina, United States
🇺🇸Scripps Clinic, San Diego, California, United States
🇺🇸Linder Clinical Trial Center, Cincinnati, Ohio, United States
Ezetimibe and Simvastatin in Dyslipidemia of Diabetes
- Conditions
- First Posted Date
- 2005-09-12
- Last Posted Date
- 2007-02-13
- Target Recruit Count
- 108
- Registration Number
- NCT00157482
- Locations
- 🇮🇹
Hospital "Ospedali Riuniti di Bergamo" - Diabetologic Unit, Bergamo, Italy
🇮🇹Hospital "Treviglio Caravaggio " - Diabetologic Unit, Treviglio, Bergamo, Italy
🇮🇹Clinical Research Center for Rare Diseases, Ranica, Bergamo, Italy
A Study to Evaluate the Effects of Ezetimibe (MK-0653) on the Postprandial (Following a Meal) Lipoprotein Response in Participants With Primary Hypercholesterolemia (High Cholesterol) (MK-0653-072)(COMPLETED)
- First Posted Date
- 2005-01-11
- Last Posted Date
- 2024-06-18
- Lead Sponsor
- Organon and Co
- Target Recruit Count
- 58
- Registration Number
- NCT00101439
Higher-Dose Ezetimibe to Treat Homozygous Sitosterolemia
- Conditions
- First Posted Date
- 2004-12-22
- Last Posted Date
- 2008-03-04
- Target Recruit Count
- 3
- Registration Number
- NCT00099996
- Locations
- 🇺🇸
National Heart, Lung and Blood Institute (NHLBI), Bethesda, Maryland, United States
Safety, Effectiveness, and Tolerability of Ezetimibe Combined With Statins for the Treatment of High Cholesterol in HIV Infected Adults
- Conditions
- First Posted Date
- 2004-12-20
- Last Posted Date
- 2012-10-29
- Target Recruit Count
- 44
- Registration Number
- NCT00099684
- Locations
- 🇺🇸
Rush-Presbyterian/St. Lukes (Chicago), Chicago, Illinois, United States
🇺🇸UCLA School of Medicine, Los Angeles, California, United States
🇺🇸University of Pennsylvania, Philadelphia, Philadelphia, Pennsylvania, United States
Comparative Efficacy Evaluation of Lipids When Treated With Niaspan & Statin or Other Lipid-Modifying Therapies-COMPELL
- Conditions
- First Posted Date
- 2004-03-12
- Last Posted Date
- 2006-11-01
- Lead Sponsor
- Kos Pharmaceuticals
- Target Recruit Count
- 300
- Registration Number
- NCT00079638
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.